| 2.13 0.15 (7.58%) | 09-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.87 |
1-year : | 16.64 |
| Resists | First : | 9.3 |
Second : | 14.25 |
| Pivot price | 1.95  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.93 |
MA(20) : | 1.9 |
| MA(100) : | 10.84 |
MA(250) : | 10.87 |
|
| MACD | MACD : | -2 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 49.1 |
D(3) : | 39.2 |
| RSI | RSI(14): 28.1 |
|||
| 52-week | High : | 19.39 | Low : | 1.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TENX ] has closed below upper band by 24.9%. Bollinger Bands are 87.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.21 - 2.22 | 2.22 - 2.22 |
| Low: | 2.04 - 2.05 | 2.05 - 2.06 |
| Close: | 2.11 - 2.13 | 2.13 - 2.14 |
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Wed, 09 Sep 2026
TENX: Future trials will enroll sicker patients to better capture strong biological effects seen in data - TradingView
Wed, 09 Sep 2026
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy - TipRanks
Wed, 09 Sep 2026
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Nigeria
Tue, 08 Sep 2026
ADAR1 Capital Management, LLC Expands Tenax Therapeutics Inc (TENX) Stake in Strategic Add - GuruFocus
Tue, 08 Sep 2026
FMR LLC reports 514,925-share stake in Tenax (NASDAQ: TENX) - Stock Titan
Sun, 06 Sep 2026
TENX Jumps As Tenax Therapeutics Pivots Phase 3 Strategy - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 104.8 (%) |
| Shares Short | 5,470 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -59.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -46 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -1.44 |
| PEG Ratio | 1.4 |
| Price to Book value | 0.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|